Acceleron Pharma Inc. (XLRN): Price and Financial Metrics


Acceleron Pharma Inc. (XLRN): $178.75

-0.93 (-0.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XLRN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

XLRN Stock Price Chart Interactive Chart >

Price chart for XLRN

XLRN Price/Volume Stats

Current price $178.75 52-week high $189.99
Prev. close $179.68 52-week low $108.82
Day low $177.06 Volume 7,884,200
Day high $179.85 Avg. volume 572,759
50-day MA $168.57 Dividend yield N/A
200-day MA $137.67 Market Cap 10.93B

Acceleron Pharma Inc. (XLRN) Company Bio


Acceleron Pharma XLRN is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company was founded in 2003 and is based in Cambridge, Massachusetts.


XLRN Latest News Stream


Event/Time News Detail
Loading, please wait...

XLRN Latest Social Stream


Loading social stream, please wait...

View Full XLRN Social Stream

Latest XLRN News From Around the Web

Below are the latest news stories about Acceleron Pharma Inc that investors may wish to consider to help them evaluate XLRN as an investment opportunity.

Sphinx Trading LP Takes $120,000 Position in Acceleron Pharma Inc. (NASDAQ:XLRN)

Sphinx Trading LP bought a new stake in shares of Acceleron Pharma Inc. (NASDAQ:XLRN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 700 shares of the biopharmaceutical companys stock, valued at approximately $120,000. Several other large investors also recently added to or reduced []

Dakota Financial News | November 22, 2021

Merck Closes Biggest Biotech Deal of the Year

The purchase of Acceleron Pharma gives Merck one more arrow in its quiver as it prepares for the patent on its blockbuster cancer therapeutic Keytruda to expire.

Yahoo | November 22, 2021

Merck completes tender offer for $11B Acceleron Pharma acquisition

No summary available.

Seeking Alpha | November 20, 2021

Acceleron Pharma (NASDAQ:XLRN) vs. Brickell Biotech (NASDAQ:BBI) Head to Head Comparison

Acceleron Pharma (NASDAQ:XLRN) and Brickell Biotech (NASDAQ:BBI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Insider and Institutional Ownership 90.4% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 14.2% []

Dakota Financial News | November 19, 2021

Fulton Bank N.A. Buys Shares of 1,507 Acceleron Pharma Inc. (NASDAQ:XLRN)

Fulton Bank N.A. bought a new stake in Acceleron Pharma Inc. (NASDAQ:XLRN) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,507 shares of the biopharmaceutical companys stock, valued at approximately $260,000. Other institutional investors and hedge funds have also recently made changes to []

Dakota Financial News | November 18, 2021

Read More 'XLRN' Stories Here

XLRN Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 41.49%
3-year 319.60%
5-year 466.02%
YTD N/A
2021 0.00%
2020 141.31%
2019 21.75%
2018 2.62%
2017 66.30%

Continue Researching XLRN

Here are a few links from around the web to help you further your research on Acceleron Pharma Inc's stock as an investment opportunity:

Acceleron Pharma Inc (XLRN) Stock Price | Nasdaq
Acceleron Pharma Inc (XLRN) Stock Quote, History and News - Yahoo Finance
Acceleron Pharma Inc (XLRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5076 seconds.